Reviparin sodium


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : SC Prophylaxis of venous thromboembolism in surgery Moderate-risk: 1,750 anti-Xa IU 2 hr pre-op. High-risk: 4,200 anti-Xa IU 12 hr pre-op. Continue once daily dosing until patient is fully mobile; at least 14 days for high-risk procedures. Thromboembolic disorders 35-45 kg: 3,500 anti-Xa IU; 46-60 kg: 4,200 anti-Xa IU and >60 kg: 6,300 anti-Xa IU. To be given twice daily w/ oral anticoagulant. Usual duration: 5-7 days.
Dosage Details
Subcutaneous
Prophylaxis of venous thromboembolism during moderate-risk surgical procedures
Adult: 1750 anti-Xa IU, given 2 hr prior to surgery. Continue once daily dosing until patient is fully mobile.

Subcutaneous
Thromboembolic disorders
Adult: Initiate treatment upon confirmation of diagnosis. 35-45 kg: 3500 anti-Xa IU; 46-60 kg: 4200 anti-Xa IU and >60 kg: 6300 anti-Xa IU. Doses to be given bid with an oral anticoagulant. Usual treatment duration with reviparin: 5-7 days.

Subcutaneous
Prophylaxis of venous thromboembolism during high-risk surgical procedures
Adult: 4200 anti-Xa IU, given 12 hr before surgery. Continue once daily dosing until patient is fully mobile and for at least 14 days.
Contraindications
Patients at serious risk of haemorrhage including blood disorders, thrombocytopaenia, peptic ulcer disease, cerebrovascular disorders, bacterial endocarditis, severe hypertension, oesophageal varices, patients who have recently undergone surgery, severe renal or hepatic impairment. IM admin. Patients who have developed thrombocytopenia with heparin. Patients with prosthetic heart valves.
Special Precautions
Elderly (women in particular); lactation; children; renal failure; diabetes mellitus. Platelet count done before and during reviparin therapy. Monitor anti-factor-Xa activity in patients with increased risk of bleeding such as elderly, renally impaired patients and patients with active bleeding.
Adverse Reactions
Vomiting, constipation, epistaxis, conjunctivitis, asthma, rhinitis. Bleeding from skin, mucosa, GI tract, wounds and genital tract; thrombosis; thromboembolism; consumption coagulopathy; Inj site necrosis; melena; petechiae; purpura; allergic features like pruritus, urticaria; nausea, headache, fever, body pain, dyspnoea and hypotension; transient alopoecia, hyperkalaemia, hypoaldosteronism; metabolic acidosis; priapism.
Potentially Fatal: Severe thrombocytopaenia with severe thromboembolic disorders and haemorrhage.
Overdosage
Overdosage may lead to haemorrhage. Severe bleeding may be decreased by slow IV admin of protamine sulfate.
Drug Interactions
Nitroglycerin infusion may diminish reviparin effect. May displace propranolol from protein-binding sites. Increased risk of haemorrhage when used with aspirin. Increased risk of hyperkalaemia when used with ACE inhibitors or angiotensin II receptor antagonists.
Potentially Fatal: Serious GI bleeding may occur when used with ketorolac.
Action
Description: Reviparin sodium, like heparin, inhibits blood clotting in vitro and in vivo by enhancing the action of antithrombin III. Antithrombin III inhibits the activity of activated clotting factors including thrombin (factor IIa) and activated factor X (factor Xa).
Pharmacokinetics:
Absorption: Absorbed from systemic circulation (SC); peak plasma concentrations after 3 hr. Bioavailability: about 95%.
Excretion: Excreted mainly in the urine. Elimination half-life: about 3 hr.
Disclaimer: This information is independently developed by MIMS based on Reviparin sodium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in